Objective: Positron Emission Tomography (PET) with F-18-Fluoro-deoxy-glucose
(FDG) emerged as a prognostic tool to predict treatment outcome in Hodgkin Lymphoma (HL).
Moreover, a FDG-PET adapted strategy is currently assessed in clinical trial to minimize the toxic
effect while maintaining the efficacy of treatment in HL. Purpose was to analyze the quantitative
parameters to support the prognostic role of FDG-PET today based on the semi-quantitative Deauville
5-point Scale (D5-PS).
Methods: This retrospective study included 53 patients diagnosed with advanced-stage HL between
2009 and 2014, enrolled in the PET response-adapted clinical trial HD 0607. FDG-PET was performed
at baseline (PET0) and after two cycles of chemotherapy (PET2). Analysis was based on
two main approaches: on the single lesion presenting the higher FDG uptake and on the five hottest
Different metabolic parameters were analyzed. Patients were classified into responders and nonresponders.
Optimal cut-offs were derived from Receiver Operating Characteristic (ROC) curves.
Results were correlated with Progression Free Survival (PFS) using Kaplan-Meier.
Results: A 71% threshold in SUVmax reduction (ΔSUVmax) was found to be the best cutoff quantitative
parameter able to identify responders vs. non-responders, also with a multivariate analysis,
joining clinical data with SUVmax. After a mean follow-up of 34.2 months (95% CI, 26.2 to 39.1),
the median PFS for non-responders was 8 months vs. not reached for responders. These results
were superimposable to that obtained by an independent group of reviewers using the D5-PS.
Conclusion: Semi-quantitative analysis by ΔSUVmax outperforms qualitative assessment by D5-PS
in predicting treatment outcome in ABVD-treated advanced-stage HL.